Syner-G BioPharma Group, a provider of integrated pharmaceutical science and regulatory consulting services to pharmaceutical and biotechnology clients, appointed Neil Butera chief commercial officer.

“We are thrilled to have Neil join the Syner-G team,” said Ron Kraus, CEO, Syner-G. “His proven commercial experience in the bio-tech industry is an invaluable asset to the current leadership team. We look forward to seeing the unique ways he will propel our services while contributing to our culture of guiding clients to a healthier tomorrow.”

Butera’s previous experience includes 15 years at Parexel where he held business development roles within the clinical research and regulatory Consulting business units before becoming the executive director, global head of inside sales for Parexel’s biotech division.

According to the company, Buter’s organization helped Parexel Biotech secure over $1 billion in new business awards.

Prior to his work at Parexel, Butera was director of business development for Ockham Development Group.

“I am honored to be chosen as the new chief commercial officer for Syner-G,” said Butera. “It is exciting to be a part of this innovative company whose services underpin the successful development of lifesaving therapies across the biopharma industry.”